Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ABUS discontinues COVID-therapeutics program:
https://www.globenewswire.com/news-release/2023/09/11/2741168/14025/en/Arbutus-Announces-Pipeline-Updates-and-Dosing-of-the-First-Subject-in-the-Phase-1a-1b-Clinical-Trial-with-AB-101-Cash-Runway-Extended.html
The company is… discontinuing its efforts to identify and develop a coronavirus combination therapy that included AB-343, its Mpro candidate, due to an unfavorable PK profile noted in the IND-enabling studies, and a potential nsp12 polymerase inhibitor.
ABUS
Arbutus Biopharma Corporation
2.01
-0.05 (-2.43%)
Volume: 410,951
Day Range: 2.00 - 2.07
Last Trade Time: 6:57:07 PM EDT
ABUS 2Q23 results—COVID phase-1 trial delayed:
https://www.globenewswire.com/news-release/2023/08/03/2717892/14025/en/Arbutus-Reports-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html
As of June 30, 2023, we had cash, cash equivalents and investments in marketable securities of $163.5 million compared to $184.3 million as of December 31, 2022. During the six months ended June 30, 2023, we used $46.9 million in operating activities, which was partially offset by $24.6 million of net proceeds from the issuance of common shares under our “at-the-market” offering program. We expect our 2023 net cash burn to range from between $90 to $95 million, excluding any proceeds received from our “at the market program”.
ABUS
Arbutus Biopharma Corporation
2.22
-0.01 (-0.45%)
Volume: 297,524
Day Range: 2.21 - 2.26
Last Trade Time: 7:20:15 PM EDT
THE LAWYER STUFF
what was disappointing ?
ABUS
Arbutus Biopharma Corporation
2.41
-0.06 (-2.43%)
Volume: 2,281,991
Day Range: 2.375 - 2.475
Last Trade Time: 6:53:42 PM EDT
DISAPPOINTING ON SUIT $ABUS
cash cow my friend $abus
ABUS
Arbutus Biopharma Corporation
2.49
-0.01 (-0.40%)
Volume: 453,317
Day Range: 2.47 - 2.52
Last Trade Time: 6:54:46 PM EDT
ABUS
Arbutus Biopharma Corporation
2.49
-0.01 (-0.40%)
Volume: 453,317
Day Range: 2.47 - 2.52
Last Trade Time: 6:54:46 PM EDT
ABUS 1Q23 results—3/31/23 cash=$178.5M:
https://www.globenewswire.com/news-release/2023/05/04/2661394/14025/en/Arbutus-Reports-First-Quarter-2023-Financial-Results-and-Corporate-Update.html
ABUS still expects to start a phase-1 trial for AB-343, a SARS-CoV-2 protease inhibitor, in 2H23.
ABUS
Arbutus Biopharma Corporation
2.505
-0.005 (-0.20%)
Volume: 419,598
Day Range: 2.48 - 2.55
Last Trade Time: 7:58:16 PM EDT
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted as late-breaker oral presentations at the Global Hepatitis Summit 2023 taking place April 25-28, 2023, in Paris.
The accepted abstracts for oral presentations are as follows:
Abstract Number: LB/O99
Session Title: Clinical 4: New HBV drug clinical developments
Session Date/Time: Thursday, April 27, 2023, 9:20 – 9:35 am
Title: 48 weeks of AB-729+nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy
Presenter: Prof. Man-Fung Yuen
Key Findings: Data from HBeAg+ subjects (Cohort K) from the AB-729-001 clinical trial showed that AB-729 treatment leads to marked HBsAg and HBeAg declines in HBeAg+ subjects, with two subjects each achieving HBsAg and HBeAg below the limit of quantitation. Additional follow-up data reported for the seven remaining HBeAg- subjects from other cohorts who elected to stop NA therapy after NA+AB-729 treatment, showed that they continue to maintain low HBV DNA levels off all therapy, and mean HBsAg levels remain 1.55 log10 below baseline levels up to one and half years after the last dose of AB-729.
Abstract Number: LB/O95
Session Title: Late Breaker Abstracts Session
Session Date/Time: Thursday, April 27, 2023, 4:45 – 5:00 pm
Title: Preclinical antiviral profiling of AB-161, an oral HBV inhibitor that destabilizes HBV RNA and suppresses HBsAg
Presenter: Angela M. Lam
Key Findings: Preclinical antiviral and mechanism of action studies were conducted for AB-161, a potent small-molecule HBV RNA destabilizer being developed as an orally administered antiviral agent for the treatment of chronic hepatitis B virus (cHBV) infection. The results showed that AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in vitro and in vivo. The differentiated anti-HBV effects of AB-161 compared to other classes of HBV inhibitors, including nucleos(t)ide analogs (NA) and capsid assembly modulators (CAM), suggest that AB-161 may be an important component in combination to provide a functional cure for cHBV.
Abstracts are available to GHS 2023 congress attendees on the congress website at https://global-hepatitis.com. The oral presentations will be available after the formal presentation has occurred on April 27, 2023, on Arbutus’ website at www.arbutusbio.com.
About AB-729
AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus. AB-729 targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA. AB-729 is currently in multiple Phase 2a clinical trials.
About AB-161
AB-161 is our next generation oral small molecule RNA destabilizer, specifically designed to target the liver. Mechanistically, RNA destabilizers target the host proteins PAPD5/7, which are involved in regulating the stability of HBV RNA transcripts. In doing so, RNA destabilizers lead to the selective degradation of HBV RNAs, thus reducing HBsAg levels and inhibiting viral replication. To provide a proprietary all-oral treatment regimen for patients with cHBV, we believe inclusion of a small molecule RNA destabilizer is key.
About HBV
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that over 290 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2.4 million people in the United States suffer from chronic HBV infection. Approximately 820,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. AB-729 is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, (including SARS-CoV-2), for which we have nominated a compound and have begun IND-enabling pre-clinical studies. In addition, we are also exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include statements about our future development plans for our product candidates; the expected cost, timing and results of our clinical development plans and clinical trials with respect to our product candidates; our expectations with respect to the release of data from our clinical trials and the expected timing thereof; our expectations and goals for our collaborations with third parties and any potential benefits related thereto; and the potential for our product candidates to achieve success in clinical trials.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus’ assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies, including uncertainties and contingencies related to the ongoing COVID-19 pandemic and patent litigation matters.
Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: anticipated pre-clinical studies and clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the tested product candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; Arbutus may not receive the necessary regulatory approvals for the clinical development of Arbutus’ products; economic and market conditions may worsen; uncertainties associated with litigation generally and patent litigation specifically; Arbutus and its collaborators may never realize the expected benefits of the collaborations; market shifts may require a change in strategic focus; and the ongoing COVID-19 pandemic could significantly disrupt Arbutus’ clinical development programs.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Primary Logo
With a median price-to-sales (or "P/S") ratio of close to 11.8x in the Biotechs industry in the United States, you could be forgiven for feeling indifferent about Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S ratio of 12.4x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
ABUS
Arbutus Biopharma Corporation
2.84
-0.11 (-3.73%)
Volume: 732,289
Day Range: 2.845 - 2.945
Bid: 2.84
Ask: 2.91
Last Trade Time: 6:51:07 PM EDT
Total Trades: 5,400
A U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corporation (NASDAQ: ABUS) patent related to a legal fight over Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines.
The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention.
Moderna challenged the patent at the PTO's Patent Trial and Appeal Board in 2018, Reuters reported, and the board invalidated it in 2019.
The Federal Circuit's decision does not affect an ongoing lawsuit Arbutus and Genevant Sciences filed against Moderna last year in Delaware for allegedly infringing other related LNP patents.
Last year in February, Arbutus and Genevant sued Moderna for infringing on their patent on a lipid nanoparticle platform that they say was crucial to delivering Moderna's widely-used COVID-19 vaccine.
The companies seek compensation.
Arbutus separately sued Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for patent infringement of five US patents last week over their COVID-19 shots.
Price Action: ABUS shares are down 1.03% at $2.88, and MRNA shares are up 0.30% at $155.72 on the last check Wednesday.
Image by Okan Caliskan from Pixabay
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
A U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corporation (NASDAQ: ABUS) patent related to a legal fight over Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines.
The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention.
Moderna challenged the patent at the PTO's Patent Trial and Appeal Board in 2018, Reuters reported, and the board invalidated it in 2019.
The Federal Circuit's decision does not affect an ongoing lawsuit Arbutus and Genevant Sciences filed against Moderna last year in Delaware for allegedly infringing other related LNP patents.
Last year in February, Arbutus and Genevant sued Moderna for infringing on their patent on a lipid nanoparticle platform that they say was crucial to delivering Moderna's widely-used COVID-19 vaccine.
The companies seek compensation.
Arbutus separately sued Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for patent infringement of five US patents last week over their COVID-19 shots.
Price Action: ABUS shares are down 1.03% at $2.88, and MRNA shares are up 0.30% at $155.72 on the last check Wednesday.
Image by Okan Caliskan from Pixabay
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
ABUS
Benzinga • 4 minutes ago
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
Connecting da dots finally/ $ABUS infringement suit on pharmacy / $ABUS
Arbutus Biopharma Corporation (NASDAQ: ABUS) and its licensee Genevant Sciences have sued Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) in the U.S. District Court for the District of New Jersey, seeking damages for infringement of five U.S. patents.
https://finance.yahoo.com/news/pfizer-slapped-additional-patent-infringement-200818206.html
Arbutus and Genevant Sciences seek compensation for the unlicensed use of patented lipid nanoparticle (LNP) delivery technologies in Pfizer/BioNTech's famed COVID-19 vaccine.
The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology, but they did not "result in a settlement."
Arbutus Biopharma sued Moderna Inc (NASDAQ: MRNA) in the Delaware court for infringing six patents in manufacturing and selling MRNA-1273, Moderna's vaccine for COVID-19.
In their lawsuit against Moderna, Arbutus said they were not looking to block the company from selling, manufacturing, or distributing MRNA-1273 but seek fair compensation.
Moderna sued Pfizer and BioNTech for patent infringement filed between 2010 and 2016 covering foundational mRNA technology.
Last year in March, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) filed separate lawsuits in the Delaware federal court against Pfizer and Moderna, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.
Price Action: ABUS shares are down 1.80% at $3.01 on the last check Tuesday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
it started wit gov't labs , in canada , stolen brought to china , dats gov't play
why should the govt being the one who is being sued. The Companies infringed the patents. They should bear any costs and litigation of infringement. If the government wants to help in their defense or reimburse them for any payments, that's a different issue (that is not ABUS's concern)
dis is connection to the last two messages $ABUS patent infringement MRNA /\ patent infringement [ $MRNA just pay the da money]
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171617393
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171617406
ABUS
-1.6544%
People pose with syringe with needle in front of displayed Moderna logo
U.S. Justice Department logo is seen at Justice Department headquarters in Washington
1 / 2
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
People pose with syringe with needle in front of displayed Moderna logo
Blake Brittain
Wed, February 15, 2023 at 10:02 AM MST
In this article:
MRNA
-2.33%
ABUS
-1.6544%
By Blake Brittain
(Reuters) - The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.
The Justice Department's court filing said the United States should be liable for any infringement of Arbutus Biopharma Corp and Genevant Sciences GmbH's patents that took place under Moderna's contract to provide shots for the government's nationwide vaccination effort.
Moderna made the same argument last year in an unsuccessful bid to win an early dismissal of the lawsuit.
Genevant declined to comment on the filing. Representatives for Moderna, the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services did not immediately respond to requests for comment Wednesday.
Warminster Township, Pennsylvania-based Arbutus and Genevant — a joint venture between Arbutus and Roivant Sciences Ltd — sued Cambridge, Massachusetts-based Moderna last year for royalties on its multi-billion-dollar COVID vaccines.
Both Moderna and Pfizer Inc have been the target of multiple patent lawsuits over their COVID vaccines, including a lawsuit brought by Moderna against Pfizer in August.
Moderna asked the Delaware court to dismiss Arbutus and Genevant's case in May, arguing it could only be brought against the government in the U.S. Court of Federal Claims. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
But U.S. District Judge Mitchell Goldberg said in November that Moderna had not yet shown that the vaccines were made for the government or with its authorization and consent under the law, and that it may have instead been an "incidental beneficiary" of the shots.
The Department of Justice responded Tuesday that Moderna should not be liable based on its contract to provide the vaccines to the government as part of Operation Warp Speed.
It said the government's liability is limited to Moderna's alleged infringing activity that took place under its U.S. contract.
The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00252.
(Reporting by Blake Brittain in Washington; Editing by David Bario and David Gregorio)
background and Pfizer statement, updates share movement) $ABUS infringement suit
April 4 (Reuters) - Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc
and its German partner BioNTech SE
in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.
Arbutus, along with its licensee Genevant Sciences, is seeking damages,
including reasonable royalties,
over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech
vaccines to carry and deliver genetic material into the body.
The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in
licensing discussions for the technology but they did not "result in a settlement".
Genevant is a joint venture between Arbutus and Roivant Sciences Ltd.
Arbutus Biopharma had also sued Moderna Inc in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents.
In their lawsuit against Moderna,
Arbutus had said they were not looking to block the drugmaker from producing or distributing the vaccines but were seeking money damages including a reasonable royalty.
Pfizer said it has not yet received the complaint.
"However,
we remain confident in our intellectual property supporting the Pfizer/BioNTech vaccine
and will vigorously defend against the allegations of the lawsuit," Pfizer said in an e-mailed statement to Reuters.
BioNTech did not immediately respond to a Reuters request for comment on the
lawsuit. Genevant and Arbutus also did not immediately respond to requests for comment.
Moderna had sued Pfizer and BioNTech in August 2022 for allegedly infringing three
patents related to their multibillion-dollar mRNA COVID-19 vaccines.
Pfizer and BioNtech are facing another patent infringement lawsuit related to their COVID-19 vaccines brought by Alnylam Pharmaceuticals Inc in March 2022.
Arbutus rose marginally in volatile trading before the bell while Pfizer and U.S.-listed shares of BioNtech were up around 0.2% each.
(Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru and Blake Brittain in Washington, D.C; Editing by Krishna Chandra Eluri)
dis could be $20 or more worth to shareholders $ABUS ingringement siut announced today 04-04-2023
ABUS/Genevant* sue PFE/BNTX re LNP technology_in_COVID_vaccine:
https://finance.yahoo.com/news/arbutus-biopharma-genevant-sciences-file-115200610.html
Arbutus Biopharma Corporation..and Genevant Sciences (Genevant) today filed a lawsuit in the U.S. District Court for the District of New Jersey against Pfizer Inc. and BioNTech SE seeking damages for infringement of U.S. Patent Nos. 9,504,651; 8,492,359; 11,141,378; 11,298,320; and 11,318,098 in the manufacture and sale of any COVID-19 mRNA-LNP vaccines. The patents relate to nucleic acid-lipid particles and their composition, manufacture, delivery and methods of use.
William Collier, President and CEO of Arbutus, stated, “…We believe that Pfizer and BioNTech could not have created and manufactured effective vaccines at such an unprecedented speed without the existing, proven and patented LNP technologies owned by Arbutus and licensed to Genevant…
ABUS presents preclinical data on COVID antiviral, AB-343 at ICAR:
https://www.globenewswire.com/news-release/2023/03/14/2627174/14025/en/Arbutus-Presents-AB-343-Data-at-the-36th-International-Conference-on-Antiviral-Research.html
ABUS is pretty far behind such players as ENTA and PRDS. AVIR is already in phase-3, but I think they have a bad drug.
ABUS 4Q22 results:
https://www.globenewswire.com/news-release/2023/03/02/2619182/14025/en/Arbutus-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Corporate-Update.html
We have nominated, AB-343 as our lead coronavirus drug candidate that inhibits the main protease (Mpro). In pre-clinical research conducted thus far, AB-343 has shown pan-coronavirus antiviral activity, no reduction in potency against known SARS-CoV-2 variants, robust activity against SARS-CoV-2 Mpro resistant strains, and a favorable drug-drug interaction profile with no need for ritonavir boosting. We expect to complete IND-enabling studies and initiate a Phase 1 clinical trial with AB-343 in the second half of 2023.
ABUS
Arbutus Biopharma Corporation
2.62
-0.12 (-4.38%)
Volume: 850,190
Day Range: 2.63 - 2.705
Last Trade Time: 7:54:29 PM EST
$ABUS patent infringement MRNA /\ patent infringement [ $MRNA just pay the da money]
ABUS
-1.6544%
People pose with syringe with needle in front of displayed Moderna logo
U.S. Justice Department logo is seen at Justice Department headquarters in Washington
1 / 2
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
People pose with syringe with needle in front of displayed Moderna logo
Blake Brittain
Wed, February 15, 2023 at 10:02 AM MST
In this article:
MRNA
-2.33%
ABUS
-1.6544%
By Blake Brittain
(Reuters) - The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.
The Justice Department's court filing said the United States should be liable for any infringement of Arbutus Biopharma Corp and Genevant Sciences GmbH's patents that took place under Moderna's contract to provide shots for the government's nationwide vaccination effort.
Moderna made the same argument last year in an unsuccessful bid to win an early dismissal of the lawsuit.
Genevant declined to comment on the filing. Representatives for Moderna, the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services did not immediately respond to requests for comment Wednesday.
Warminster Township, Pennsylvania-based Arbutus and Genevant — a joint venture between Arbutus and Roivant Sciences Ltd — sued Cambridge, Massachusetts-based Moderna last year for royalties on its multi-billion-dollar COVID vaccines.
Both Moderna and Pfizer Inc have been the target of multiple patent lawsuits over their COVID vaccines, including a lawsuit brought by Moderna against Pfizer in August.
Moderna asked the Delaware court to dismiss Arbutus and Genevant's case in May, arguing it could only be brought against the government in the U.S. Court of Federal Claims. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
But U.S. District Judge Mitchell Goldberg said in November that Moderna had not yet shown that the vaccines were made for the government or with its authorization and consent under the law, and that it may have instead been an "incidental beneficiary" of the shots.
The Department of Justice responded Tuesday that Moderna should not be liable based on its contract to provide the vaccines to the government as part of Operation Warp Speed.
It said the government's liability is limited to Moderna's alleged infringing activity that took place under its U.S. contract.
The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00252.
(Reporting by Blake Brittain in Washington; Editing by David Bario and David Gregorio)
I AM SURPRISED NO DIVY TO SHAREHOLDERS ALL THESE YRS.
THANK YOU, $ABUS
ABUS
Arbutus Biopharma Corporation
2.95
0.00 (0.00%)
Volume: 706,064
Day Range: 2.845 - 3.025
Last Trade Time: 7:56:21 PM EST
Can someone remind me what we are waiting for besides the lawsuit ?
ABUS
Arbutus Biopharma Corporation
2.67
-0.04 (-1.48%)
Volume: 3,072,962
Day Range: 2.61 - 2.80
Last Trade Time: 6:45:00 PM EST
Hell Yea, here we go!!!